Design Therapeutics, Inc.

Design Therapeutics, Inc.

DSGN · Nasdaq

Design Therapeutics, Inc. (DSGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Design Therapeutics, Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 83 days

EPS estimate

-0.35

Revenue estimate

0

Past earnings

03 Aug 2026
EPS actual
-0.32 (+7.1%)
estimate -0.34
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
28 Apr 2026
EPS actual
-0.29 (+8.4%)
estimate -0.32
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
09 Mar 2026
EPS actual
-0.27 (+23.7%)
estimate -0.35
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
05 Nov 2025
EPS actual
-0.30 (+12.6%)
estimate -0.34
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Design Therapeutics beat consensus estimates in its latest earnings report, with EPS of -$0.32 versus an estimate of -$0.3443, while revenue met estimates at $0. In the prior quarter, EPS also beat expectations and revenue met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Pratik Shah
Employees
56
IPO date
29 Mar 2021
ISIN
US25056L1035
Website
designtx.com

Frequently asked questions

When does Design Therapeutics, Inc. (DSGN) next report earnings?

Design Therapeutics, Inc. (DSGN) is scheduled to report earnings on November 11, 2026.

What was Design Therapeutics, Inc.'s most recent earnings date?

Design Therapeutics, Inc. (DSGN) last reported earnings on August 3, 2026.

Where is Design Therapeutics, Inc. stock listed?

Design Therapeutics, Inc. (DSGN) is listed on Nasdaq.